Conference call to discuss the strategic collaboration with Amgen

Stockholm, 4 October, 2016. Nuevolution AB (publ) (NUE.ST) announce that the company’s executive management will host a conference call and webcast to discuss the strategic collaboration with Amgen on Tuesday 4 October at 14:00 CEST. Access to the event can be obtained as follows:

LIVE access on Tuesday 4 October at 14:00 CEST

Telephone numbers:

SE: +46 85 664 2662

DK: +45 3544 5575

UK: +44 20 3008 9808

US: +1 855 7532 235

Webcast will be available at in the Investors section and at

REPLAY access

Webcast replay will be available at in the Investors section and at

For more information, please contact:

Alex Haahr Gouliaev

Chief Executive Officer

Nuevolution AB (publ)

Phone: +45 7020 0987


Henrik D. Simonsen

Chief Financial Officer

Nuevolution AB (publ)

Phone: +45 3913 0947


About Nuevolution

Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, headquartered in Copenhagen, Denmark. Nuevolution partners its proprietary discovery platform and programs with pharmaceutical and biotechnology companies to seek future benefit of patients in need of novel medical treatment options. Nuevolution’s internal programs are focused on therapeutically important targets within inflammation, oncology and immuno-oncology.

This information is information that Nuevolution AB (publ) is obliged to make public pursuant to the Securities Market Act. The information was sent for publication on Tuesday 4 October, 10:00 (CEST).

Nuevolution AB (publ) is listed at Nasdaq First North Premier in Stockholm, Sweden (ticker: NUE.ST). Västra Hamnen Corporate Finance AB acts as Certified Adviser to Nuevolution AB (publ). More information about Nuevolution can be found on:

About Us

Nuevolution is a biotechnology company with a unique business model, where continuous revenue generation and risk mitigation represent primary objectives. This strategy is executed by a “multiple shots at goal” approach in combination with reduced research costs, where simultaneous development of multiple programs in parallel is made possible. Nuevolution is the inventor of Chemetics®. Chemetics® is a patent protected drug discovery research platform, which enables identification of small molecule (tablet based) drug candidates much more effectively and at lower cost than what is possible by other conventional methods. Nuevolution applies its research platform for the identification and development of its own pipeline of drug candidates for treatment of cancer and chronic inflammatory diseases Nuevolution applies a business model that is unique for a biotechnology company with a primary focus on revenue generation and risk minimization (i.e. lower cost development) by having a number of programs developed in parallel. Nuevolution is the inventor of Chemetics® , a patent protected drug discovery platform which enables efficient discovery of novel chemical small molecule leads for specific indications addressing disease targets within the company’s therapeutic focus areas


Documents & Links